key: cord-0940680-omli3a9q
authors: Chiang, Teresa PY; Alejo, Jennifer L.; Mitchell, Jonathan; Kim, Jake D.; Abedon, Aura T.; Karaba, Andrew H.; Thomas, Letitia; Levan, Macey L.; Garonzik‐Wang, Jacqueline M.; Avery, Robin K.; Pekosz, Andrew; Clarke, William A.; Warren, Daniel S.; Tobian, Aaron A. R.; Massie, Allan B.; Segev, Dorry L.; Werbel, William A.
title: Heterologous Ad.26.COV2.S versus homologous BNT162b2/mRNA‐1273 as a third dose in solid organ transplant recipients seronegative after two‐dose mRNA vaccination
date: 2022-05-03
journal: Am J Transplant
DOI: 10.1111/ajt.17061
sha: 6e17182971a455b4df20261412d26abd6fc8b2f2
doc_id: 940680
cord_uid: omli3a9q

Heterologous vaccination (“mixing platforms”) for the third (D3) dose of SARS‐CoV‐2 vaccine is a potential strategy to improve antibody responses in solid organ transplant recipients (SOTRs), but data are mixed regarding potential differential immunogenicity. We assessed for differences in immunogenicity and tolerability of homologous (BNT162b2 or mRNA‐1273; D3‐mRNA) versus heterologous (Ad.26.COV2.S; D3‐JJ) D3 among 377 SARS‐CoV‐2‐infection naïve SOTRs who remained seronegative after two mRNA vaccines. We measured anti‐spike titers and used weighted Poisson regression to evaluate seroconversion and development of high‐titers, comparing D3‐JJ to D3‐mRNA, at 1‐, 3‐, and 6 month post‐D3. 1‐month post‐D3, seroconversion (63% vs. 52%, p = .3) and development of high‐titers (29% vs. 25%, p = .7) were comparable between D3‐JJ and D3‐mRNA recipients. 3 month post‐D3, D3‐JJ recipients were 1.4‐fold more likely to seroconvert (80% vs. 57%, weighted incidence‐rate‐ratio: wIRR = (1.10)1.40(1.77), p = .006) but not more likely to develop high‐titers (27% vs. 22%, wIRR = (0.44)0.92(1.93), p = .8). 6 month post‐D3, D3‐JJ recipients were 1.41‐fold more likely to seroconvert (88% vs. 59%, wIRR = (1.04) 1.41(1.93), p = .029) and 2.63‐fold more likely to develop high‐titers (59% vs. 21%, wIRR = (1.38)2.63(5.00), p = .003). There was no differential signal in alloimmune events or reactogenicity between platforms. SOTRs without antibody response after two mRNA vaccines may derive benefit from heterologous Ad.26.COV2.S D3.

SARS-CoV-2 infection causes substantial morbidity and mortality in solid organ transplant recipients (SOTRs). [1] [2] [3] [4] Vaccination holds promise to reduce COVID-19 severity in SOTRs, but a significant subset does not develop antibody response after two-and three-dose mRNA vaccine series, [5] [6] [7] [8] which likely contributes to higher rates of COVID-19 breakthrough after vaccination. 4 Heterologous vaccination ("mixing platforms") is one potential mode to augment aspects of immune sero-response, [9] [10] [11] [12] but data are limited in SOTRs. [13] [14] [15] In one randomized trial of kidney transplant recipients who remained seronegative after two mRNA vaccine doses, seroconversion rates 1 month after receiving Ad. 26 .COV2.S as a third dose (D3) was no different than after receiving a homologous mRNA vaccine. 16 However, studies in the general population indicate that SARS-CoV-2 binding antibody and neutralization might demonstrate a delayed increase after Ad. 26 .COV2.S. [17] [18] [19] It is therefore possible that a difference in vaccine immunogenicity could emerge beyond the early timepoint of 1-month after receipt of an Ad. 26 .COV2.S when compared with an additional mRNA vaccine as D3 in vulnerable SOTRs.

The primary goal of this study was to compare the antibody kinetics after D3 with Ad.26.COV2.S (D3-JJ) versus an mRNA vaccine (D3-mRNA) up to 6 month post-D3 in a large real-world cohort of SOTR who remained seronegative after receiving two mRNA SARS-CoV-2 vaccines. Vaccine reactogenicity, alloimmune complications, and incidence of breakthrough infections were also assessed between D3-JJ and D3-mRNA recipients.

Adult (age ≥ 18 years) SOTRs across the US were recruited for our national observational study as previously described. 6 

Anti-spike titers were measured pre-D3 and 1-month (14-45 days, n = 304 measurements), 3-month (60-120 days, n = 272 measurements), 6-month (135-210 days, n = 93 measurements) post-D3 using one of two clinical assays: the Roche Elecsys ® anti-SARS-CoV-2 S enzyme immunoassay (EIA), testing for total antibody to the SARS-CoV-2 S-receptor binding domain protein (anti-RBD, range < 0.8, 2500 U/ml, seropositive: ≥0.8 U/ml), or the EUROIMMUN EIA, testing for S1 domain of the SARS-CoV-2 spike protein (anti-S1, range 

Poisson regression with robust standard error was used to evaluate seropositivity (anti-RBD ≥ 0.8 U/ml or anti-S1 ≥ 1.1 AU) or wIRR = 0.44 0.92 1.93 , p = .8). 6 month post-D3, D3-JJ recipients were 1.41-fold more likely to seroconvert (88% vs. 59%, wIRR = 1.04 1.41 1.93 , p = .029) and 2.63-fold more likely to develop high-titers (59% vs. 21%, wIRR = 1.38 2.63 5.00 , p = .003). There was no differential signal in alloimmune events or reactogenicity between platforms. SOTRs without antibody response after two mRNA vaccines may derive benefit from heterologous Ad.26.COV2.S D3.

antibodies, heterologous, SARS-CoV-2, transplant, vaccine development of high-titers (anti-RBD ≥ 250 U/ml or anti-S1 ≥ 4 AU), comparing D3-JJ recipients to D3-mRNA recipients at 1-, 3-, and 6 month post-D3, after weighting for age (doubly-robust) and organ received (kidney vs. no-kidney). Separate weights were computed for each time point. We assessed the standardized differences of the weighted populations at 1, 3, and 6 months to confirm that the weighted populations were comparable in terms of age and organ received at each time point.

We repeated analyses stratified by assay type for each time point post hoc as sensitivity analysis to assess whether inferences differed. Similar to the primary analysis, Poisson regression with robust standard error was used to evaluate both seropositivity and development of high-titers, comparing D3-JJ recipients to D3-mRNA recipients at 1, 3, and 6 month post-D3 using either anti-RBD or anti-S1 assays. As in the main analysis, we weighted for age and organ type (kidney vs. no-kidney), except for 3 month post-D3 (only weighted for age) and 6 month post-D3 (unweighted) among participants tested with anti-S1 due to sample size constraints.

Among the D3-mRNA recipients, a subgroup analysis compared the post-D3 seropositivity and development of high-titers between recipients of three consecutive BNT162b2 vaccines to recipients of three consecutive mRNA-1273 vaccines using Fisher's exact test.

Serial follow up surveys were used to ascertain serious adverse events after vaccination (collected at 1-week post-D3), including alloimmune complications such as rejection, as well as incident myocarditis, anaphylactoid reactions, or thrombotic events including vaccine-induced thrombotic thrombocytopenia (VITT). Incident COVID-19 diagnoses or reception of monoclonal antibodies were also ascertained by scheduled follow-up survey, including two additional surveys during the omicron wave (January 2022). Results were reported with two-sided p < .05 as level of significance.

Among 377 SOTRs, the 40 D3-JJ recipients and 337 D3-mRNA recipients were similar in terms of sex (48% female vs 59% female, 

Using only samples tested on the anti-RBD assay, D3-JJ recipients were more likely than D3-mRNA recipients to be anti-RBD positive at 1-month post-D3 compared to D3-mRNA (D3-JJ vs. D3-mRNA: 77% vs. 50%, p = .022; wIRR = 1.31 1.65 2.08 , p < .001) and at 3 month post-D3 (D3-JJ vs. D3-mRNA: 85% vs. 59%, p = .027; wIRR = 1.10 1.42 1.84 , p = .007). This relationship did not meet statistical significance at 6 months post-D3 (D3-JJ vs. D3-mRNA: 83% vs. 57%, p = .11; wIRR = 0.90 1.36 2.03 , p = .14) ( Table S1a ). In the smaller subset of recipient samples tested on the anti-S1 assay, there was no significant difference in anti-S1 positivity at 1-month (D3-JJ vs. D3-mRNA: 38% vs. Table S1b ).

There was no difference in seropositivity post-D3 comparing the recipients of three consecutive BNT162b2 to three consecutive mRNA-1273 vaccines; 52%/51% (p = .9), 57%/57% (p > .99), and 59%/65% (p = .8) at 1, 3, and 6 months post-D3, respectively (Table S2 ). Receipt of three consecutive mRNA-1273 vaccines was associated with high-titer seroconversion at 6 month post-D3 (39% vs. 14%, p = .029), but this was not observed between groups at any other time point.

Severe adverse reactions after D3 were rare; one D3-mRNA recipient (0.3%) reported fluid overload and a systemic inflammatory reaction temporally associated with mRNA-1273. Otherwise, the most common local adverse reaction to D3 was arm pain (D3-JJ vs. (Table S3) . 

In this prospective cohort study of SOTRs seronegative after two-dose mRNA vaccine series, we found that recipients of Ad. 26 been documented in the SOTR population. [17] [18] [19] Additionally, equipoise remains about seroconversion rates and longer-term immunogenicity between receipt of BNT162b2 versus mRNA-1273 vaccines, with some suggestion of improved immune sero-response with mRNA-1273 receipt. 25, 26 We did not, however, note differential seroconversion at 1, 3 and 6 month post-D3, though there was a signal particularly at 6 months for higher prevalence of high-titer sero-response in mRNA-1273 recipients. Regardless, many SOTRs remained seronegative after receiving D3-mRNA, which is consistent with historical cohorts, e.g., Benotmane 28 Additionally, cellular responses were not measured, which TA B L E 2 Anti-spike seropositivity following Ad.26.COV2.S versus BNT162b2/mRNA-1273 as third dose of COVID vaccine among solid organ transplant recipients seronegative after two doses Bold indicates statistically significant weighted odds ratios. a After weighting procedure for imbalanced population.

COVID-19-associated mortality among kidney transplant recipients and candidates in the United States

Poor outcomes of COVID-19 in lung transplant recipients

COVID-19 in solid organ transplantation: results of the national

Risk of breakthrough SARS-CoV-2 infections in adult transplant recipients

Antibody response after a third dose of the mRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients with minimal serologic response to 2 doses

Safety and immunogenicity of a third dose of SARS-CoV-2 vaccine in solid organ transplant recipients: a case series

Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients

Prospective evaluation of COVID-19 vaccine responses across a broad spectrum of immunocompromising conditions: the COVICS study

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial

Homologous and heterologous covid-19 booster vaccinations

Association of homologous and heterologous vaccine boosters with COVID-19 incidence and severity in Singapore

To mix or not to mix? A rapid systematic review of heterologous prime-boost covid-19 vaccination

A 'mix and match' approach to SARS-CoV-2 vaccination

Efficacy and safety of third dose of the COVID-19 vaccine among solid organ transplant recipients: a systemic review and meta-analysis

Cellular immunity predominates over humoral immunity after homologous and heterologous mRNA and vector-based COVID-19 vaccine regimens in solid organ transplant recipients

Comparison of SARS-CoV-2 antibody response 4 weeks after homologous vs heterologous third vaccine dose in kidney transplant recipients

Interim results of a phase 1-2a trial of Ad26.COV2.S covid-19 vaccine

Immunogenicity of the Ad26.COV2.S vaccine for COVID-19

Comparative immunogenicity and effectiveness of mRNA-1273, BNT162b2, and Ad26.COV2.S COVID-19 vaccines

Weak antibody response to three doses of mRNA vaccine in kidney transplant recipients treated with belatacept

A third dose of SARS-CoV-2 vaccine increases neutralizing antibodies against variants of concern in solid organ transplant recipients

Neutralization of SARS-CoV-2 variants in transplant recipients after two and three doses of mRNA-1273 vaccine : secondary analysis of a randomized trial

Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients

Effective communication of standard errors and confidence intervals

Comparison of SARS-CoV-2 antibody response following vaccination with BNT162b2 and mRNA-1273

Antibody response after a third dose of the mRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients with minimal serologic response to 2 doses

Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients

Neutralization against Omicron variant in transplant recipients after three doses of mRNA vaccine

Humoral and cellular immune response and safety of two-dose SARS-CoV-2 mRNA-1273 vaccine in solid organ transplant recipients

Discordance between SARS-CoV-2-specific cell-mediated and antibody responses elicited by mRNA-1273 vaccine in kidney and liver transplant recipients